期刊
NANOMEDICINE
卷 7, 期 12, 页码 1813-1825出版社
FUTURE MEDICINE LTD
DOI: 10.2217/NNM.12.73
关键词
bcl-2; cytosolic delivery; high-density lipoprotein; nanoparticle; siRNA; SR-BI
资金
- Canadian Institutes of Health Research
- Ontario Institute for Cancer Research through Government of Ontario
- China-Canada Joint Health Research Initiative (CIHR) [CCI-102936, NSFC-30911120489]
- Natural Sciences and Engineering Research Council of Canada
- Joey and Toby Tanenbaum/Brazilian Ball Chair in Prostate Cancer Research
The main challenge for RNAi therapeutics lies in systemic delivery of siRNA to the correct tissues and transporting them into the cytoplasm of targeted cells, at safe, therapeutic levels. Recently, we developed a high-density lipoprotein-mimicking peptide phospholipid scaffold (HPPS) and demonstrated its direct cytosolic delivery of siRNA in vitro, thereby bypassing endosomal trapping. Aim: We investigate the in vivo implementation of HPPS for siRNA delivery. Method & results: After systemic administration in KB tumor-bearing mice, HPPS prolonged the blood circulation time of cholesterol-modified siRNA (chol-siRNA) by a factor of four, improved its biodistribution and facilitated its uptake in scavenger receptor class B type I overexpressed tumors. For therapeutic targeting to the bcl-2 gene, the HPPS-chol-si-bcl-2 nanoparticles downregulated Bcl-2 protein, induced enhanced apoptosis (2.5-fold) in tumors when compared with controls (saline, HPPS, HPPS-chol-si-scramble and chol-si-bcl-2) and significantly inhibited tumor growth with no adverse effect. Conclusion: HPPS is a safe, efficient nanocarrier for RNAi therapeutics in vivo. Original submitted 2 December 2011; Revised submitted 19 April 2012; Published online 26 July 2012
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据